While both gemcitabine - docetaxel and gemcitabine - vinorelbine are regimens with significant activity and acceptable toxicity they require larger randomized trials before they can be said to be standard of care 虽然健择泰索帝和健择诺维本均为具有显著活性和可接受毒性的方案，在它们可被称为标准治疗方案之前还需要进行更大规模的随机临床研究以评估其疗效和不良反应。
